Everolimus extends PFS for HR positive, HER2 negative breast cancer

Share :
Published: 9 Dec 2016
Views: 2166
Rating:
Save
Dr Noah Kornblum - Montefiore Medical Center, New York, USA

Dr Kornblum speaks with ecancer at the San Antonio Breast Cancer Symposium 2016 about results from the PrECOG 0102 trial, a randomised, double-blind phase II trial of everolimus vs placebo in combination with fulvestrant from HR /HER- metastatic breast cancer for patients resistant of aromatase inhibitor therapy.

He describes that the addition of everolimus doubled median PFS to 10.4 months, with adverse events at a higher, but manageable, severity, consistent with previous assessment of everolimus in the BOLERO-2 trial.

These results were first presented at a press conference, with video available here.